Yes, Kisqali Treats Cancer
Kisqali (ribociclib) is a prescription medication approved to treat certain types of breast cancer in adults.[1] It belongs to a class of drugs called CDK4/6 inhibitors, which slow cancer cell growth by blocking proteins that control the cell cycle.
Which Cancers Does Kisqali Target?
Kisqali is specifically FDA-approved for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that is advanced or metastatic.[1] Doctors often use it combined with an aromatase inhibitor as initial endocrine-based therapy, or with fulvestrant after prior endocrine therapy. It's not approved for other cancers like lung, prostate, or early-stage breast cancer.
How Does Kisqali Work?
It targets cyclin-dependent kinases 4 and 6 (CDK4/6), enzymes that help cancer cells divide. By inhibiting them, Kisqali halts tumor progression in HR+/HER2- breast cancers, which rely on these pathways.[1]
Common Side Effects Patients Report
Fatigue, nausea, diarrhea, hair loss, low white blood cell counts (neutropenia), and liver problems occur frequently. Serious risks include infections, lung issues, and heart rhythm changes—monitoring with blood tests and EKGs is standard.[1]
Who Makes Kisqali and What's the Cost?
Novartis manufactures Kisqali. Treatment costs around $5,000–$6,000 per 28-day cycle without insurance, though patient assistance programs can lower it.[2]
When Does Kisqali's Patent Expire?
Key U.S. patents on ribociclib expire between 2029 and 2034, with some facing challenges from generics makers. Check DrugPatentWatch.com for exact expiry dates, litigation status, and Paragraph IV challenges.[3]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208082s029lbl.pdf
[2] Novartis Patient Assistance: https://www.novartis.com/us-en/patients
[3] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/KISQALI